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Abstract 
Infiltrative cerebral gliomas remain a 
neurosurgical challenge despite the latest 
achievements in neuroimaging techniques 
and microsurgical approaches. In this paper 
the authors present their experience in 85 
cases of stereotactic biopsies performed for 
infiltrative, multicentric and deep-seated 
cerebral gliomas. The stereotactic and 
neuroimagistic tools used for these 
procedures included the Leksell stereotactic 
system and the software: Stereotactic 
Planning System (SPS), NTPS 8.2. The 
histopatological results (according to World 
Health Organization (WHO) classification) 
were: 51 cases of glioblastomas (grade IV) 
(60%), 7 cases of anaplastic astrocytomas 
(grade III) (8,2%), 13 cases of grade II 
diffuse astrocytomas (15,3%), 6 cases of 
grade I astrocytomas (7,1%), one case of 
grade II oligodendroglioma (1,2%), 3 cases 
of anaplastic oligodendrogliomas (grade III) 
(3,5%), one case of grade I ganglioglioma 
(1,2%), one case of anaplastic ganglioglioma 
(grade III) (1,2%), and 2 cases of anaplastic 
ependymomas (grade III) (2,3%). In 21 
cases (24,7%) the immunohistochemistry 
has been performed in order to obtain an 
accurate histopathological result.  In this 
series, the early postoperative mortality was 
0%, with no cases of clinically significant 
hemorrhages after biopsy procedures. 
Temporary increase of neurological deficits 
has been noticed in 7 patients (8,2%). In 
conclusion, image-guided stereotactic 
biopsy represents now a safe and accurate 
diagnostic method for cerebral gliomas, 
which can favorably influence the 
therapeutic management of the patients. 
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Introduction 
Primary brain tumors represent a major 
health problem. Their incidence is 
approximately 10 new cases at 100.000 
inhabitants per year, but the frequency has 
been continuously increasing during the 
last decades (3). Within this pathology, 
there is an important group represented by 
cerebral gliomas, which ranks first as 
frequency and severity of the clinical 
outcome. According to WHO classification 
of tumors, cerebral gliomas can be divided 
in four grades (20). Excepting grade I 
gliomas, which can be often cured by 
surgical resection, grades II to IV are 
virtually impossible to be cured with 
current therapies. Glioblastoma (grade IV) 
is the most frequent and malignant glial 
tumor and it is associated with a dismal 
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prognosis expressed by a limited survival 
expectancy of the patients (between 6 and 
12 months) (16). Anaplastic astrocytoma 
(grade III) has also a rapid evolution to a 
fatal outcome with a survival period of 
approximately 2-3 years (2). Grade II 
gliomas have a slower growth and a better 
outcome, but they affect younger patients 
and have a progressive evolution to higher 
degrees of malignancy (grade III-IV) (8). 
One of the main features of grade II, III and 
IV gliomas is the invasion of surrounding 
brain tissue, which precludes a gross-total 
surgical resection (5). Therefore, 
stereotactic biopsy, a minimal invasive 
surgical procedure, is indicated in many 
cases of gliomas, especially those which are 
multicentric, have an infiltrative growth 
pattern or are located in eloquent or 
surgical inaccessible areas of the brain. In 
this paper the authors describe their 
experience in 85 consecutive cases of 
infiltrative, multicentric and deep-seated 
gliomas which underwent stereotactic 
biopsy in our clinic.  
Material and method 
Eighty-five consecutive patients with 
infiltrative, multicentric and deep-seated 
supratentorial gliomas have been admitted 
in our clinic, between November 2008 and 
March 2012. All patients underwent the 
stereotactic biopsy according to the 
standard protocols. The anticoagulant or 
antiplatelet medication, if present, had been 
stopped at least 7 days before the surgical 
procedure. Any abnormalities in the 
coagulogram or platelet count were rule out 
before biopsy. The corticosteroid therapy 
had been initiated before the surgical 
procedure in the majority of the patients. 
The stereotactic and neuroimagistic tools 
used for these procedures included the 
Leksell stereotactic system and the latest 
software: Stereotactic Planning System 
(SPS), NTPS 8.2. For application of the 
coordinate frame, the local anesthetics 
lidocaine 1% (approximately 1,5-2 ml per 
each pin site) has been used. For anxious 
patients and children, we administrated 
mild sedatives. In three cases (one small 
child and two confused adult patients) we 
used general anesthesia. In the majority of 
cases (60 cases – 70,6%) the MRI 1,5 Tesla 
(Philips Integra) was used for scanning the 
fiducial system. In the rest of the cases, 
including the patients under general 
anesthesia, we used the CT scan (Philips, 
Brilliance). In several cases, we made the 
image fusion with the MR images 
previously acquired. Therefore, in the 
majority of the cases the planning was 
performed on MR images: gadolinium-
enhanced T1-weighted, 1 mm slice 
thickness and T2-weighted, 2 mm slice 
thickness. During the planning procedure, 
we chose the target within the centre of 
homogenously enhancing lesion, or within 
the gadolinium enhanced periphery of the 
ring enhancing lesion. If the lesions did not 
enhanced, we chose the target within the 
maximum area of hypo-intense T1-
weighted signal and hyper-intense T2-
weighted signal, respectively. When CT 
scan was employed, the planning was 
performed on enhanced 1,5 mm slice 
thickness CT images. The shortest 
trajectories, which avoid eloquent areas and 
vessels, were chosen. For operatory 
procedure, we usually employed general 
anesthesia, for patient comfort. Between 4 
and 8 millimeter size tumor samples per 
patient were obtained using the side-cutting 
Sedan I biopsy needle, which were sent to 
the histopathological department. In several 
cases, there were minor intraoperative 
hemorrhages at the biopsy site. In all those 
cases we did not redraw the needle; instead 
we irrigated with saline solution for several 
minutes until the hemorrhage stopped. All 
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patients underwent postoperative CT 
scanning. The patients had received 
corticotherapy, prophylactic antibiotics and 
prophylactic anticonvulsivant therapy until 
they were discharged from our department.   
Results 
The median age of the patients was 51 
years (ranged between 7 and 75 years) and 
the cohort included 7 children (8,2%) and 
78 adults (91,8%). There were 44 women 
(51,8%) and 41 men (48,2%) in our series. 
The age distribution in the population 
cohort was: 1 - 10 years: 4 cases (4,7%); 11 - 
20 years: 7 cases (8,2%); 21 - 30 years: 3 
cases (3,5%); 31 - 40 years: 14 cases 
(16,5%); 41 - 50 years: 12 cases (14,1%); 51 
– 60 year: 23 cases (27,1%), 61 – 70 years: 
19 cases (22,4%) and 71-80 years: 3 cases 
(3,5%).  
There were 73 cases (85,9%) of unifocal 
tumors, 10 cases of multicentric tumors 
(11,8%) and two cases of gliomatosis 
cerebri (2,3%). The main location of 
unifocal tumors were in thalamus in 14 
cases (16,5%), right cerebral peduncle in 
one case (1,2%), posterior third ventricle in 
one case (1,2%), in basal ganglia and insula 
in 16 cases (18,8%). Seventeen cases were 
restricted to the white matter of cerebral 
hemispheres (20%). In 20 cases, there was a 
significant invasion in corpus callosum 
(23,5%). Four cases had the typical aspect of 
butterfly glioblastomas (4,7%) (Figure 1). 
 
 
Figure 1   MR gadolinium-enhance T1-weighted images of a glioblastoma involving the splenium of the corpus 
callosum (“butterfly” glioblastoma) 
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The histopatological results (according 
to World Health Organization (WHO) 
classification) were: 51 cases of 
glioblastomas (grade IV) (60%), 7 cases of 
anaplastic astrocytomas (grade III) (8,2%), 
13 cases of grade II diffuse astrocytomas 
(15,3%), 6 cases of grade I astrocytomas 
(7,1%), one case of grade II 
oligodendroglioma (1,2%), 3 cases of 
anaplastic oligodendrogliomas (grade III) 
(3,5%), one case of grade I ganglioglioma 
(1,2%), one case of anaplastic ganglioglioma 
(grade III) (1,2%), and 2 cases of anaplastic 
ependymomas (grade III) (2,3%). In four 
cases the initial results were inconclusive 
(4,7%). Of these four cases, after a 
histopathological reexamination (including 
the immunohistochemistry techniques), 
two cases (2,3%) have been interpreted as 
grade II fibrillary astrocytomas, one case 
(1,2%) as grade I pilocytic astrocytoma and 
one case (1,2%) as grade I ganglioglioma. In 
21 cases (24,7%) the 
immunohistochemistry was performed in 
order to obtain an accurate 
histopathological result. 
Two cases of difficulty to approach, deep 
located gliomas (one case in the posterior 
part of third ventricle and one case in 
thalamus) are illustrated in figures 2-5.
 
 
Figure 2   11 year-old girl with posterior third ventricle tumor mass – gadolinium-enhanced T1-weighted MR 
planning images 
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Figure 3   11 year-old girl with posterior third ventricle tumor mass without neurological deficits – 
Postoperative unenhanced CT scan; Histopathological result: grade II astrocytoma 
 
 
Figure 4   49 year-old female with right thalamic tumor mass – MR planning images 
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Figure 5   49 year-old female with right thalamic tumor mass – Postoperative unenhanced CT scan. 
Histopathological result: glioblastoma 
 
In this series, the early postoperative 
(within 7 days after biopsy) mortality was 0. 
One case of death (1,2%) occurred at 10 
days after biopsy. This was a case of 
infiltrating glioblastoma, located in right 
basal ganglia and insula, with mass effect 
and poor neurological status (somnolence 
and left hemiparesis), for whom the 
caregivers refused open surgery. At four 
days after biopsy, the general and 
neurological status of the patient suddenly 
deteriorated. CT scan showed an increased 
peritumoral edema and no sign of 
hemorrhage. Despite of the high doses of 
cortisone and mannitol administrated, the 
final outcome was unfavorable. There was 
no case of clinically significant hemorrhages 
after biopsy procedures. In 9 patients 
(10,6%), CT scan showed evidence of 
minor hemorrhage at the biopsy site, which 
did not influence the neurological outcome 
of the patients. Temporary increasing of 
neurological deficits has been noticed in 7 
patients (8,2%). The incidence of 
immediate postoperative seizures was 7,1% 
(2 cases of generalized and 4 cases of partial 
motor seizures). In three cases (3,5%) there 
were signs of local infection which required 
intravenous antibiotics administration for 7 
days. The median hospitalization time of 
the patients was 3, 5 days. 
Discussions 
Stereotactic biopsy is a minimally 
invasive diagnostic procedure that takes 
small tumor samples with minimal risk for 
patients. The first use of a human 
stereotactic apparatus is credited to Ernest 
A. Spiegel and Henry T. Wycis, in 1947 
(15). The field of stereotactic surgery has 
constantly developed since this first 
important step. The major achievement in 
combining the stereotactic frames and CT 
or MR scans, involved the development of a 
fiducial system (1). The availability of 
image-based stereotactic surgery opened 
new perspectives for the management of 
brain tumors. The most common 
stereotactic procedure became biopsy (7) 
and among the expansive intracranial 
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masses, the gliomas were the most suitable 
lesions for this approach, because many of 
them are infiltrative, or multicentric. 
In this paper, the authors present their 
experience in 85 cases of gliomas with 
infiltrative or multicentric growth pattern, 
or located in eloquent area of the brain; all 
these features precluded the open surgical 
approach of the lesions. Therefore, the 
stereotactic biopsy remained the only 
options for these patients. For all 
procedures we used the Leksell stereotactic 
system which, in our opinion, is one of the 
most precise and easy to handle system due 
to its simple arc-centered principle. The 
popularity of Leksell stereotactic system is 
reflected by literature data. Therefore, the 
most important stereotactic apparatus are 
the Cosman-Roberts-Wells in USA, and 
the Leksell and Riechert- Mundinger 
systems in Europe (6, 7). 
In our series, there was no major 
hemorrhagic accident. The explanation is 
that in the majority of cases we employed 
the high resolution MR images for 
planning the stereotactic procedure. The 
combination of gadolinium-enhanced T1-
weighted, 1 mm thickness slices and T2-
weighted, 2 mm thickness slices, enabled us 
to accurately visualize even the small blood 
vessels within the tumor centre or tumor 
periphery. The versatility of the stereotactic 
software, which includes the “path view” 
option, reveals to neurosurgeon all the 
structures (including the blood vessels) 
encountered along the trajectory path from 
the entry point to the target point. The 
importance of MR images in increasing the 
safety of stereotactic biopsy is underlined by 
the literature data. Therefore, the CT-
guided biopsy series have a relatively high 
incidence of major hemorrhagic 
complications, up to 5, 6% (11, 12, 14). On 
the other hand, the MR-guided biopsy 
series have a significant lower frequency of 
major hemorrhagic complications to as low 
as approximately 0.7% (13, 19). A similar 
correlation, but referred to the frequency of 
minor hemorrhage events, was observed by 
the authors of this paper. Between 
November 2008 and February 2011, we 
employed either MR or CT for stereotactic 
planning. However, the incidence of minor 
hemorrhages, revealed by the postoperative 
CT scan, strongly correlated with the type 
of neuroimaging tools used for planning 
procedure (CT scan with a higher 
incidence versus MR with a lower 
incidence). As a result of these findings, 
since March 2011, MR images were 
included in planning protocol for all cases. 
Therefore, the authors of this paper 
emphasize the importance of MR images 
(gadolinium-enhanced T1-weighted and 
T2-weighted) for stereotactic planning in 
order to avoid the hemorrhagic 
complications which may occur during the 
biopsy procedure. 
The immunohistochemistry technique is 
a valuable diagnostic tool, which assess a 
precise diagnosis, including the malignity 
grade of glioma by evaluating the 
expression of Ki-67 marker, even in the 
presence of a very small amount of tissue 
sample. In our study, the 
immunohistochemistry technique was 
employed in approximately 25% of cases, 
especially when a small amount of tissue 
was available for histopathological analyses. 
If the molecular analysis of tumor samples 
were employed, the stereotactic biopsy 
could assess not only the diagnosis, but also 
could evaluate the prognosis and the 
response rate to chemotherapy. The 
relations between certain molecular 
markers and genetic mutations and the 
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predictability of response to chemotherapy 
have been previously demonstrated. Thus, 
it is known that in the case of 
oligodendrogliomas, the presence of the 
1p/19q deletion is a favorable prognostic to 
chemotherapy (4, 9). The stereotactic group 
from Munich (F.W. Kreth) demonstrated 
the value of stereotactic biopsy procedure in 
assessing the molecular profiling of 
infiltrative low-grade gliomas (for TP53 
mutation and loss of heterozygosity of 
1p/19q) and glioblastoma (for MGMT 
methylation) with important implications 
in the prognosis and therapeutic 
management of the patients (10, 17, 18). 
Therefore, one of the main priorities of our 
stereotactic group is to develop the 
molecular analysis of tumor samples in 
order not only to obtain an accurate 
diagnosis, but also to improve the 
therapeutic management of the patients. 
Conclusions 
The image-guided stereotactic biopsy 
represents now a safe and accurate 
diagnostic method for cerebral gliomas, 
which can favorably influence the 
therapeutic management of the patients. 
Using the MR images for planning 
improves the safety of stereotactic 
procedure by decreasing the incidence of 
hemorrhagic complications which may 
occur during biopsy. 
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